Neoantigen Cancer Vaccines Market Size, Share & Trends Analysis Report by Vaccine Type (Personalized Neoantigen Vaccines, Off-the-Shelf Neoantigen Vaccines), Technology Platform, Neoantigen Type, Cancer Type, Delivery Route, Therapy Type, Development Phase, End User and Geography (North America, Europe, Asia Pacific, Middle East, Africa and South America) – Global Industry Data, Trends and Forecasts, 2026–2035
Market Overview:
As per MarketGenics, the global neoantigen cancer vaccines market is experiencing significant growth, valued at USD 0.6 billion in 2025 and projected to reach USD 5.1 billion by 2035, expanding at a CAGR of 23.9% during the forecast period.
|
|
|
Segmental Data Insights |
|
|
Demand Trends |
|
|
Competitive Landscape |
|
|
Strategic Development |
|
|
Future Outlook & Opportunities |
|
Neoantigen Cancer Vaccines Market Size, Share, and Growth
“To our knowledge, the GT-30 clinical study provides the first definitive demonstration of a personalized cancer vaccine enhancing clinical response to anti-PD-1 therapy by inducing new, neoantigen-specific T cells which traffic to the tumor,” said Ildiko Csiki, MD, PhD, chief medical officer of Geneos. “The fact that the PTCV regimen has produced this important result in a form of cancer as immunologically ‘cold’ as HCC, leading to multiple complete responses and a doubling of objective response versus PD-1, is incredibly promising and shows the therapeutic potential of personalized cancer vaccines for cancer patients.”
The expansion of clinical development to various tumor types is increasing the therapeutic applications and the patient base that neoantigen vaccines can reach. For instance, in June 2026, Moderna’s oncology strategy is expanding beyond individualized vaccines toward shared-antigen approaches, including mRNA-4194 targeting frameshift antigens associated with mismatch-repair deficiency.
In addition, positive clinical data is driving the validation of personalized neoantigen vaccines and promoting broader development across solid-tumor indications. For instance, BioNTech has reported long-lasting neoantigen-specific immune responses following treatment with autogene cevumeran, paving the way for the further development of personalized cancer immunotherapies in Phase 2 studies in melanoma patients.
Adjacent opportunities for the global neoantigen-cancer-vaccines-market include next-generation sequencing & genomic profiling, AI-driven neoantigen prediction, mRNA cancer vaccine platforms, immune checkpoint inhibitor combinations, personalized oncology manufacturing. These adjacent markets have the potential to support the neoantigen vaccine ecosystem, expedite clinical translation, increase scalability, and drive revenue growth throughout precision oncology.
Neoantigen Cancer Vaccines Market Dynamics and Trends
Driver: AI-Enabled Neoantigen Selection is Improving Precision of Personalized Cancer Vaccines
- The use of artificial intelligence in conjunction with genomic profiling is improving the identification, prioritization, and assessment of tumor-specific neoantigens that can be used to develop personalized cancer vaccines with greater precision.
- For instance, in April 2026, NEC Corporation and Transgene entered into a license agreement for TG4050 in the treatment of resected HPV-negative head and neck cancer, leveraging NEC's AI-based neoantigen prediction tool and Transgene's personalized myvac vaccine platform.
- The development highlights the growing convergence of computational technologies with genomic and immunological processes for more accurate vaccine design with the potential to expand to other cancer indications.
- AI-based neoantigen selection can increase the personalization, target identification, and clinical development of personalized cancer vaccines.
Restraint: Complex Individualized Manufacturing Continues to Constrain Commercial Scalability
- Patient neoantigen vaccines are complex to operate because an integrated workflow is required from tumor biopsy, genomic sequencing, computational analysis, selection of neoantigens, vaccine design, manufacture, quality control, and clinical administration.
- Customized vaccines continue to face several commercialization hurdles, including quality, production time, logistics and cost of manufacture, and economies of scale. For instance, BioNTech’s iNeST platform necessitates patient-specific vaccine design via sequencing and bioinformatics and requires GMP manufacturing that is on-demand and includes multiple patient-specific neoantigens.
- The complexity of manufacturing, the high cost of production and lack of scalability can act as a limiting factor for widespread adoption and slow down-market expansion.
Opportunity: Preventive Neoantigen Vaccination Can Expand Applications Beyond Active Cancer Treatment
- Neoantigen vaccines are increasingly being investigated for cancer interception and prevention, creating opportunities beyond therapeutic treatment of established tumors. In January 2026, Nouscom released a clinical study in Phase 1b/2 that assessed NOUS-209 in patients with Lynch syndrome, who have high inherited risk of colorectal and other cancers.
- The program exemplifies the possibility of the neoantigen vaccine as a therapy for existing malignancies, but also as a prevention for genetically susceptible sub-populations. This application would allow for increased access to the population, earlier intervention and new pathways in preventive oncology.
- Cancer-interception strategies could expand the addressable market by extending neoantigen vaccines into preventive oncology.
Key Trend: Broadening Neoantigen Vaccine Platforms Beyond Conventional mRNA Approaches
- The neoantigen vaccine pipeline is expanding rapidly, with a growing variety of mRNA, DNA and viral-vector platforms designed to maximize the number of antigens delivered, activate the immune system, increase delivery efficiency, and enhance therapeutic efficacy.
- The GT-EPIC platform of Geneos Therapeutics involves custom DNA plasmids coding for multiple patient-specific neoantigens, and GT-30 has shown neoantigen-specific T-cell responses in patients with hepatocellular carcinoma.
- Concurrently, NEC and Transgene are advancing TG4050, an individualized viral-vector vaccine incorporating AI-selected neoantigens. The advances indicate a growing technological difference between vaccine platforms and the diversification of application in difficult cancer indications.
- Platform diversification is anticipated to increase technology competition, expand therapeutic applications and market potential across various cancer types.
Neoantigen Cancer Vaccines Market Analysis and Segmental Data
Personalized Neoantigen Vaccines Dominate Global Neoantigen Cancer Vaccines Market
- The personalized neoantigen vaccines segment dominates the global neoantigen cancer vaccines market due to their precision-oncology applications that rely on patients’ unique tumor mutations, which allow highly specific immune response against the patient's tumor.
- The progressively strong clinical validation in various solid tumors is bolstering the uptake potential. For instance, BioNTech SE is pushing on with the development of autogene cevumeran in colorectal and pancreatic cancer in Phase 2, continuing its investment in targeted mRNA neoantigen therapy.
- The company's platform leverages each patient's tumor mutation landscape to create a tailored vaccine, further highlighting the clinical and technological benefits of patient-specific treatments.
- The rise in clinical validation and personalized treatment options will be expected to bolster personalized vaccine uptake and stimulate the market for neoantigen cancer vaccines to grow.
North America Leads Global Neoantigen Cancer Vaccines Market Demand
- North America leads the neoantigen cancer vaccines market is owing to investments in neoantigen vaccination by the U.S. government, while precision-oncology research is also driving clinical development, thereby bolstering the expansion of the region's neoantigen cancer vaccines market.
- For instance, The U.S. National Cancer Institute is advancing precision immunotherapy research with programs currently underway in clinical trials for personalized neoantigen vaccines for pancreatic and other hard-to-treat cancers.
- Additionally, North America boasts advanced biotechnology capabilities and has a robust clinical-trial infrastructure, which is driving advanced individualized neoantigen therapies to market. For example, Moderna is progressing V940 through several indications in cancer, with strong capabilities in U.S. biotechnology and clinical-development.
- Strong government support, advanced biotechnology capabilities, and extensive clinical infrastructure are expected to accelerate innovation, clinical adoption, and market growth across North America.
Neoantigen Cancer Vaccines Market Ecosystem
The global neoantigen cancer vaccines market is moderately consolidated with BioNTech, Moderna, Agenus, Nouscom, and Geneos Therapeutics. with leading developers leveraging individualized mRNA, DNA, and viral-vector platforms to advance precision cancer immunotherapy. BioNTech’s autogene cevumeran uses patient-specific tumor neoantigens, while Moderna’s V940 applies an individualized mRNA approach across multiple cancer indications.
Government and research institutions are also strengthening the technological ecosystem. The U.S. National Cancer Institute (NCI) in April 2025 shared clinical trial data backing personalized neoantigen vaccines for pancreatic and kidney cancer, urging continued interest in precision immunotherapy at the institution.
Technological progress is now primarily geared towards higher targeting and longevity of the immune system. BioNTech reported that 8/16 patients with autogene cevumeran had strong neoantigen-specific T-cell responses that lasted for three years or longer.
The growth of clinical validation, government-sponsored research, and developments in personalized vaccine platforms will likely drive innovation, enhance therapeutic effectiveness, and contribute to the continued expansion of the market.
Recent Development and Strategic Overview:
- In January 2026, BioNTech designated autogene cevumeran as a strategic Phase 2 program, with clinical data anticipated from its ctDNA-positive colorectal cancer study, reinforcing its focus on individualized neoantigen immunotherapy.
- In August 2025, Moderna initiated the Phase 2 V940-012 study evaluating V940 with pembrolizumab, expanding individualized neoantigen vaccine development for unresectable melanoma and strengthening the company’s broader personalized oncology pipeline.
Report Scope
|
Detail |
|
|
Market Size in 2025 |
USD 0.6 Bn |
|
Market Forecast Value in 2035 |
USD 5.1 Bn |
|
Growth Rate (CAGR) |
23.9% |
|
Forecast Period |
2026 – 2035 |
|
Historical Data Available for |
2021 – 2024 |
|
Market Size Units |
US$ Billion for Value |
|
Report Format |
Electronic (PDF) + Excel |
|
North America |
Europe |
Asia Pacific |
Middle East |
Africa |
South America |
|
|
|
|
|
|
|
Companies Covered |
|||||
|
|
|
||||
Neoantigen Cancer Vaccines Market Segmentation and Highlights
|
Segment |
Sub-segment |
|
Neoantigen Cancer Vaccines Market, By Vaccine Type |
|
|
Neoantigen Cancer Vaccines Market, By Technology Platform |
|
|
Neoantigen Cancer Vaccines Market, By Neoantigen Type |
|
|
Neoantigen Cancer Vaccines Market, By Cancer Type |
|
|
Neoantigen Cancer Vaccines Market, By Delivery Route |
|
|
Neoantigen Cancer Vaccines Market, By Therapy Type |
|
|
Neoantigen Cancer Vaccines Market, By Development Phase |
|
|
Neoantigen Cancer Vaccines Market, By End User |
|
Frequently Asked Questions
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Neoantigen Cancer Vaccines Market Outlook
- 2.1.1. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2026-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global Neoantigen Cancer Vaccines Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Advances in next-generation sequencing and neoantigen prediction technologies
- 4.1.1.2. Rising adoption of personalized and precision oncology approaches
- 4.1.1.3. Growing integration of mRNA platforms and combination immunotherapy
- 4.1.2. Restraints
- 4.1.2.1. High complexity and cost of patient-specific vaccine manufacturing
- 4.1.2.2. Tumor heterogeneity and immunosuppressive tumor microenvironment limiting clinical efficacy
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global Neoantigen Cancer Vaccines Market Demand
- 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
- 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
- 4.7.2.1. Y-o-Y Growth Trends
- 4.7.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global Neoantigen Cancer Vaccines Market Analysis, by Vaccine Type
- 6.1. Key Segment Analysis
- 6.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Vaccine Type, 2021-2035
- 6.2.1. Personalized Neoantigen Vaccines
- 6.2.2. Off-the-Shelf Neoantigen Vaccines
- 7. Global Neoantigen Cancer Vaccines Market Analysis, by Technology Platform
- 7.1. Key Segment Analysis
- 7.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology Platform, 2021-2035
- 7.2.1. mRNA-based Vaccines
- 7.2.2. Peptide-based Vaccines
- 7.2.3. DNA-based Vaccines
- 7.2.4. Dendritic Cell-based Vaccines
- 7.2.5. Viral Vector-based Vaccines
- 7.2.6. Lipid Nanoparticle (LNP)-based Vaccines
- 7.2.7. Cell-based Vaccines
- 7.2.8. Synthetic Long Peptide (SLP) Vaccines
- 7.2.9. Others
- 8. Global Neoantigen Cancer Vaccines Market Analysis, by Neoantigen Type
- 8.1. Key Segment Analysis
- 8.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Neoantigen Type, 2021-2035
- 8.2.1. Somatic Mutation-derived Neoantigens
- 8.2.2. Frameshift Mutation Neoantigens
- 8.2.3. Fusion-derived Neoantigens
- 8.2.4. Splice Variant Neoantigens
- 8.2.5. Shared Tumor-associated Neoantigens
- 8.2.6. Tumor-specific Neoantigens
- 9. Global Neoantigen Cancer Vaccines Market Analysis, by Cancer Type
- 9.1. Key Segment Analysis
- 9.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Cancer Type, 2021-2035
- 9.2.1. Melanoma
- 9.2.2. Non-Small Cell Lung Cancer (NSCLC)
- 9.2.3. Colorectal Cancer
- 9.2.4. Pancreatic Cancer
- 9.2.5. Bladder/Urothelial Cancer
- 9.2.6. Renal Cell Carcinoma
- 9.2.7. Head & Neck Cancer
- 9.2.8. Glioblastoma/Brain Tumors
- 9.2.9. Others (Breast, Ovarian, Hepatocellular, etc.)
- 10. Global Neoantigen Cancer Vaccines Market Analysis, by Delivery Route
- 10.1. Key Segment Analysis
- 10.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Delivery Route, 2021-2035
- 10.2.1. Intradermal
- 10.2.2. Subcutaneous
- 10.2.3. Intramuscular
- 10.2.4. Intravenous
- 10.2.5. Intratumoral
- 11. Global Neoantigen Cancer Vaccines Market Analysis, by Therapy Type
- 11.1. Key Segment Analysis
- 11.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapy Type, 2021-2035
- 11.2.1. Monotherapy
- 11.2.2. Combination with Immune Checkpoint Inhibitors
- 11.2.3. Combination with Chemotherapy
- 11.2.4. Combination with Targeted Therapy
- 11.2.5. Combination with Radiotherapy
- 11.2.6. Combination with Cell Therapy
- 11.2.7. Combination with Cytokine Therapy
- 12. Global Neoantigen Cancer Vaccines Market Analysis, by Development Phase
- 12.1. Key Segment Analysis
- 12.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Development Phase, 2021-2035
- 12.2.1. Preclinical
- 12.2.2. Phase I
- 12.2.3. Phase II
- 12.2.4. Phase III
- 12.2.5. Approved/Commercial
- 13. Global Neoantigen Cancer Vaccines Market Analysis, by End User
- 13.1. Key Segment Analysis
- 13.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
- 13.2.1. Hospitals
- 13.2.2. Cancer Specialty Centers
- 13.2.3. Academic & Research Institutes
- 13.2.4. Biotechnology Companies
- 13.2.5. Pharmaceutical Companies
- 13.2.6. Contract Manufacturing Organizations
- 14. Global Neoantigen Cancer Vaccines Market Analysis, by Region
- 14.1. Key Findings
- 14.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
- 14.2.1. North America
- 14.2.2. Europe
- 14.2.3. Asia Pacific
- 14.2.4. Middle East
- 14.2.5. Africa
- 14.2.6. South America
- 15. North America Neoantigen Cancer Vaccines Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. North America Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Vaccine Type
- 15.3.2. Technology Platform
- 15.3.3. Neoantigen Type
- 15.3.4. Cancer Type
- 15.3.5. Delivery Route
- 15.3.6. Therapy Type
- 15.3.7. Development Phase
- 15.3.8. End User
- 15.3.9. Country
- 15.3.9.1. USA
- 15.3.9.2. Canada
- 15.3.9.3. Mexico
- 15.4. USA Neoantigen Cancer Vaccines Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Vaccine Type
- 15.4.3. Technology Platform
- 15.4.4. Neoantigen Type
- 15.4.5. Cancer Type
- 15.4.6. Delivery Route
- 15.4.7. Therapy Type
- 15.4.8. Development Phase
- 15.4.9. End User
- 15.5. Canada Neoantigen Cancer Vaccines Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Vaccine Type
- 15.5.3. Technology Platform
- 15.5.4. Neoantigen Type
- 15.5.5. Cancer Type
- 15.5.6. Delivery Route
- 15.5.7. Therapy Type
- 15.5.8. Development Phase
- 15.5.9. End User
- 15.6. Mexico Neoantigen Cancer Vaccines Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Vaccine Type
- 15.6.3. Technology Platform
- 15.6.4. Neoantigen Type
- 15.6.5. Cancer Type
- 15.6.6. Delivery Route
- 15.6.7. Therapy Type
- 15.6.8. Development Phase
- 15.6.9. End User
- 16. Europe Neoantigen Cancer Vaccines Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Europe Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Vaccine Type
- 16.3.2. Technology Platform
- 16.3.3. Neoantigen Type
- 16.3.4. Cancer Type
- 16.3.5. Delivery Route
- 16.3.6. Therapy Type
- 16.3.7. Development Phase
- 16.3.8. End User
- 16.3.9. Country
- 16.3.9.1. Germany
- 16.3.9.2. United Kingdom
- 16.3.9.3. France
- 16.3.9.4. Italy
- 16.3.9.5. Spain
- 16.3.9.6. Netherlands
- 16.3.9.7. Nordic Countries
- 16.3.9.8. Poland
- 16.3.9.9. Russia & CIS
- 16.3.9.10. Rest of Europe
- 16.4. Germany Neoantigen Cancer Vaccines Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Vaccine Type
- 16.4.3. Technology Platform
- 16.4.4. Neoantigen Type
- 16.4.5. Cancer Type
- 16.4.6. Delivery Route
- 16.4.7. Therapy Type
- 16.4.8. Development Phase
- 16.4.9. End User
- 16.5. United Kingdom Neoantigen Cancer Vaccines Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Vaccine Type
- 16.5.3. Technology Platform
- 16.5.4. Neoantigen Type
- 16.5.5. Cancer Type
- 16.5.6. Delivery Route
- 16.5.7. Therapy Type
- 16.5.8. Development Phase
- 16.5.9. End User
- 16.6. France Neoantigen Cancer Vaccines Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Vaccine Type
- 16.6.3. Technology Platform
- 16.6.4. Neoantigen Type
- 16.6.5. Cancer Type
- 16.6.6. Delivery Route
- 16.6.7. Therapy Type
- 16.6.8. Development Phase
- 16.6.9. End User
- 16.7. Italy Neoantigen Cancer Vaccines Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Vaccine Type
- 16.7.3. Technology Platform
- 16.7.4. Neoantigen Type
- 16.7.5. Cancer Type
- 16.7.6. Delivery Route
- 16.7.7. Therapy Type
- 16.7.8. Development Phase
- 16.7.9. End User
- 16.8. Spain Neoantigen Cancer Vaccines Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Vaccine Type
- 16.8.3. Technology Platform
- 16.8.4. Neoantigen Type
- 16.8.5. Cancer Type
- 16.8.6. Delivery Route
- 16.8.7. Therapy Type
- 16.8.8. Development Phase
- 16.8.9. End User
- 16.9. Netherlands Neoantigen Cancer Vaccines Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Vaccine Type
- 16.9.3. Technology Platform
- 16.9.4. Neoantigen Type
- 16.9.5. Cancer Type
- 16.9.6. Delivery Route
- 16.9.7. Therapy Type
- 16.9.8. Development Phase
- 16.9.9. End User
- 16.10. Nordic Countries Neoantigen Cancer Vaccines Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Vaccine Type
- 16.10.3. Technology Platform
- 16.10.4. Neoantigen Type
- 16.10.5. Cancer Type
- 16.10.6. Delivery Route
- 16.10.7. Therapy Type
- 16.10.8. Development Phase
- 16.10.9. End User
- 16.11. Poland Neoantigen Cancer Vaccines Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Vaccine Type
- 16.11.3. Technology Platform
- 16.11.4. Neoantigen Type
- 16.11.5. Cancer Type
- 16.11.6. Delivery Route
- 16.11.7. Therapy Type
- 16.11.8. Development Phase
- 16.11.9. End User
- 16.12. Russia & CIS Neoantigen Cancer Vaccines Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Vaccine Type
- 16.12.3. Technology Platform
- 16.12.4. Neoantigen Type
- 16.12.5. Cancer Type
- 16.12.6. Delivery Route
- 16.12.7. Therapy Type
- 16.12.8. Development Phase
- 16.12.9. End User
- 16.13. Rest of Europe Neoantigen Cancer Vaccines Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Vaccine Type
- 16.13.3. Technology Platform
- 16.13.4. Neoantigen Type
- 16.13.5. Cancer Type
- 16.13.6. Delivery Route
- 16.13.7. Therapy Type
- 16.13.8. Development Phase
- 16.13.9. End User
- 17. Asia Pacific Neoantigen Cancer Vaccines Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Asia Pacific Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Vaccine Type
- 17.3.2. Technology Platform
- 17.3.3. Neoantigen Type
- 17.3.4. Cancer Type
- 17.3.5. Delivery Route
- 17.3.6. Therapy Type
- 17.3.7. Development Phase
- 17.3.8. End User
- 17.3.9. Country
- 17.3.9.1. China
- 17.3.9.2. India
- 17.3.9.3. Japan
- 17.3.9.4. South Korea
- 17.3.9.5. Australia and New Zealand
- 17.3.9.6. Indonesia
- 17.3.9.7. Malaysia
- 17.3.9.8. Thailand
- 17.3.9.9. Vietnam
- 17.3.9.10. Rest of Asia Pacific
- 17.4. China Neoantigen Cancer Vaccines Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Vaccine Type
- 17.4.3. Technology Platform
- 17.4.4. Neoantigen Type
- 17.4.5. Cancer Type
- 17.4.6. Delivery Route
- 17.4.7. Therapy Type
- 17.4.8. Development Phase
- 17.4.9. End User
- 17.5. India Neoantigen Cancer Vaccines Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Vaccine Type
- 17.5.3. Technology Platform
- 17.5.4. Neoantigen Type
- 17.5.5. Cancer Type
- 17.5.6. Delivery Route
- 17.5.7. Therapy Type
- 17.5.8. Development Phase
- 17.5.9. End User
- 17.6. Japan Neoantigen Cancer Vaccines Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Vaccine Type
- 17.6.3. Technology Platform
- 17.6.4. Neoantigen Type
- 17.6.5. Cancer Type
- 17.6.6. Delivery Route
- 17.6.7. Therapy Type
- 17.6.8. Development Phase
- 17.6.9. End User
- 17.7. South Korea Neoantigen Cancer Vaccines Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Vaccine Type
- 17.7.3. Technology Platform
- 17.7.4. Neoantigen Type
- 17.7.5. Cancer Type
- 17.7.6. Delivery Route
- 17.7.7. Therapy Type
- 17.7.8. Development Phase
- 17.7.9. End User
- 17.8. Australia and New Zealand Neoantigen Cancer Vaccines Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Vaccine Type
- 17.8.3. Technology Platform
- 17.8.4. Neoantigen Type
- 17.8.5. Cancer Type
- 17.8.6. Delivery Route
- 17.8.7. Therapy Type
- 17.8.8. Development Phase
- 17.8.9. End User
- 17.9. Indonesia Neoantigen Cancer Vaccines Market
- 17.9.1. Country Segmental Analysis
- 17.9.2. Vaccine Type
- 17.9.3. Technology Platform
- 17.9.4. Neoantigen Type
- 17.9.5. Cancer Type
- 17.9.6. Delivery Route
- 17.9.7. Therapy Type
- 17.9.8. Development Phase
- 17.9.9. End User
- 17.10. Malaysia Neoantigen Cancer Vaccines Market
- 17.10.1. Country Segmental Analysis
- 17.10.2. Vaccine Type
- 17.10.3. Technology Platform
- 17.10.4. Neoantigen Type
- 17.10.5. Cancer Type
- 17.10.6. Delivery Route
- 17.10.7. Therapy Type
- 17.10.8. Development Phase
- 17.10.9. End User
- 17.11. Thailand Neoantigen Cancer Vaccines Market
- 17.11.1. Country Segmental Analysis
- 17.11.2. Vaccine Type
- 17.11.3. Technology Platform
- 17.11.4. Neoantigen Type
- 17.11.5. Cancer Type
- 17.11.6. Delivery Route
- 17.11.7. Therapy Type
- 17.11.8. Development Phase
- 17.11.9. End User
- 17.12. Vietnam Neoantigen Cancer Vaccines Market
- 17.12.1. Country Segmental Analysis
- 17.12.2. Vaccine Type
- 17.12.3. Technology Platform
- 17.12.4. Neoantigen Type
- 17.12.5. Cancer Type
- 17.12.6. Delivery Route
- 17.12.7. Therapy Type
- 17.12.8. Development Phase
- 17.12.9. End User
- 17.13. Rest of Asia Pacific Neoantigen Cancer Vaccines Market
- 17.13.1. Country Segmental Analysis
- 17.13.2. Vaccine Type
- 17.13.3. Technology Platform
- 17.13.4. Neoantigen Type
- 17.13.5. Cancer Type
- 17.13.6. Delivery Route
- 17.13.7. Therapy Type
- 17.13.8. Development Phase
- 17.13.9. End User
- 18. Middle East Neoantigen Cancer Vaccines Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Middle East Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Vaccine Type
- 18.3.2. Technology Platform
- 18.3.3. Neoantigen Type
- 18.3.4. Cancer Type
- 18.3.5. Delivery Route
- 18.3.6. Therapy Type
- 18.3.7. Development Phase
- 18.3.8. End User
- 18.3.9. Country
- 18.3.9.1. Turkey
- 18.3.9.2. UAE
- 18.3.9.3. Saudi Arabia
- 18.3.9.4. Israel
- 18.3.9.5. Rest of Middle East
- 18.4. Turkey Neoantigen Cancer Vaccines Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Vaccine Type
- 18.4.3. Technology Platform
- 18.4.4. Neoantigen Type
- 18.4.5. Cancer Type
- 18.4.6. Delivery Route
- 18.4.7. Therapy Type
- 18.4.8. Development Phase
- 18.4.9. End User
- 18.5. UAE Neoantigen Cancer Vaccines Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Vaccine Type
- 18.5.3. Technology Platform
- 18.5.4. Neoantigen Type
- 18.5.5. Cancer Type
- 18.5.6. Delivery Route
- 18.5.7. Therapy Type
- 18.5.8. Development Phase
- 18.5.9. End User
- 18.6. Saudi Arabia Neoantigen Cancer Vaccines Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Vaccine Type
- 18.6.3. Technology Platform
- 18.6.4. Neoantigen Type
- 18.6.5. Cancer Type
- 18.6.6. Delivery Route
- 18.6.7. Therapy Type
- 18.6.8. Development Phase
- 18.6.9. End User
- 18.7. Israel Neoantigen Cancer Vaccines Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Vaccine Type
- 18.7.3. Technology Platform
- 18.7.4. Neoantigen Type
- 18.7.5. Cancer Type
- 18.7.6. Delivery Route
- 18.7.7. Therapy Type
- 18.7.8. Development Phase
- 18.7.9. End User
- 18.8. Rest of Middle East Neoantigen Cancer Vaccines Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Vaccine Type
- 18.8.3. Technology Platform
- 18.8.4. Neoantigen Type
- 18.8.5. Cancer Type
- 18.8.6. Delivery Route
- 18.8.7. Therapy Type
- 18.8.8. Development Phase
- 18.8.9. End User
- 19. Africa Neoantigen Cancer Vaccines Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Africa Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Vaccine Type
- 19.3.2. Technology Platform
- 19.3.3. Neoantigen Type
- 19.3.4. Cancer Type
- 19.3.5. Delivery Route
- 19.3.6. Therapy Type
- 19.3.7. Development Phase
- 19.3.8. End User
- 19.3.9. Country
- 19.3.9.1. South Africa
- 19.3.9.2. Egypt
- 19.3.9.3. Nigeria
- 19.3.9.4. Algeria
- 19.3.9.5. Rest of Africa
- 19.4. South Africa Neoantigen Cancer Vaccines Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Vaccine Type
- 19.4.3. Technology Platform
- 19.4.4. Neoantigen Type
- 19.4.5. Cancer Type
- 19.4.6. Delivery Route
- 19.4.7. Therapy Type
- 19.4.8. Development Phase
- 19.4.9. End User
- 19.5. Egypt Neoantigen Cancer Vaccines Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Vaccine Type
- 19.5.3. Technology Platform
- 19.5.4. Neoantigen Type
- 19.5.5. Cancer Type
- 19.5.6. Delivery Route
- 19.5.7. Therapy Type
- 19.5.8. Development Phase
- 19.5.9. End User
- 19.6. Nigeria Neoantigen Cancer Vaccines Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Vaccine Type
- 19.6.3. Technology Platform
- 19.6.4. Neoantigen Type
- 19.6.5. Cancer Type
- 19.6.6. Delivery Route
- 19.6.7. Therapy Type
- 19.6.8. Development Phase
- 19.6.9. End User
- 19.7. Algeria Neoantigen Cancer Vaccines Market
- 19.7.1. Country Segmental Analysis
- 19.7.2. Vaccine Type
- 19.7.3. Technology Platform
- 19.7.4. Neoantigen Type
- 19.7.5. Cancer Type
- 19.7.6. Delivery Route
- 19.7.7. Therapy Type
- 19.7.8. Development Phase
- 19.7.9. End User
- 19.8. Rest of Africa Neoantigen Cancer Vaccines Market
- 19.8.1. Country Segmental Analysis
- 19.8.2. Vaccine Type
- 19.8.3. Technology Platform
- 19.8.4. Neoantigen Type
- 19.8.5. Cancer Type
- 19.8.6. Delivery Route
- 19.8.7. Therapy Type
- 19.8.8. Development Phase
- 19.8.9. End User
- 20. South America Neoantigen Cancer Vaccines Market Analysis
- 20.1. Key Segment Analysis
- 20.2. Regional Snapshot
- 20.3. South America Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 20.3.1. Vaccine Type
- 20.3.2. Technology Platform
- 20.3.3. Neoantigen Type
- 20.3.4. Cancer Type
- 20.3.5. Delivery Route
- 20.3.6. Therapy Type
- 20.3.7. Development Phase
- 20.3.8. End User
- 20.3.9. Country
- 20.3.9.1. Brazil
- 20.3.9.2. Argentina
- 20.3.9.3. Rest of South America
- 20.4. Brazil Neoantigen Cancer Vaccines Market
- 20.4.1. Country Segmental Analysis
- 20.4.2. Component Vaccine Type
- 20.4.3. Technology Platform
- 20.4.4. Neoantigen Type
- 20.4.5. Cancer Type
- 20.4.6. Delivery Route
- 20.4.7. Therapy Type
- 20.4.8. Development Phase
- 20.4.9. End User
- 20.5. Argentina Neoantigen Cancer Vaccines Market
- 20.5.1. Country Segmental Analysis
- 20.5.2. Vaccine Type
- 20.5.3. Technology Platform
- 20.5.4. Neoantigen Type
- 20.5.5. Cancer Type
- 20.5.6. Delivery Route
- 20.5.7. Therapy Type
- 20.5.8. Development Phase
- 20.5.9. End User
- 20.6. Rest of South America Neoantigen Cancer Vaccines Market
- 20.6.1. Country Segmental Analysis
- 20.6.2. Vaccine Type
- 20.6.3. Technology Platform
- 20.6.4. Neoantigen Type
- 20.6.5. Cancer Type
- 20.6.6. Delivery Route
- 20.6.7. Therapy Type
- 20.6.8. Development Phase
- 20.6.9. End User
- 21. Key Players/ Company Profile
- 21.1. Agenus Inc.
- 21.1.1. Company Details/ Overview
- 21.1.2. Company Financials
- 21.1.3. Key Customers and Competitors
- 21.1.4. Business/ Industry Portfolio
- 21.1.5. Product Portfolio/ Specification Details
- 21.1.6. Pricing Data
- 21.1.7. Strategic Overview
- 21.1.8. Recent Developments
- 21.2. BioNTech SE
- 21.3. Creative Biolabs
- 21.4. Geneos Therapeutics, Inc.
- 21.5. Intavis Peptide Services GmbH
- 21.6. ISA Pharmaceuticals B.V.
- 21.7. Moderna, Inc.
- 21.8. NEC Bio B.V.
- 21.9. Neogene Therapeutics (AstraZeneca plc)
- 21.10. Nouscom AG
- 21.11. Nykode Therapeutics AS
- 21.12. The Merck Group
- 21.13. Others
- 21.1. Agenus Inc.
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Research Design
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
Research Approach
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
Research Methods
Desk / Secondary Research
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is a combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase, and others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players' product portfolio
Primary Research
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources include primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
Forecasting Factors and Models
Forecasting Factors
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Forecasting Models / Techniques
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Research Analysis
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Validation & Evaluation
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation